Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, notice convening AGM 7 March 200220 Feb 2002
Genmab, grant of warrants.15 Feb 2002
Genmab, announces year-end financial results11 Feb 2002
Genmab, preliminary announcement of annual accounts 200111 Feb 2002
Genmab, financial calendar 200231 Jan 2002
Genmab, to acquire land for manufacturing facility in Denmark23 Jan 2002
Genmab, change of management21 Jan 2002
Genmab, Dr. Ernst Schweizer appointed Head of Business Development at Genmab
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
21 Jan 2002
Genmab, Oxford Glycosciences, Medarex and Genmab announce comprehensive campaign to Treat breast cancer9 Jan 2002
Genmab, to present at the 2002 JP Morgan H&Q Healtcare Conference7 Jan 2002
Genmab, to Present at the 2002 JP Morgan H&Q Healtcare Conference (correction)7 Jan 2002
Genmab, appoints Rachel Gravesen17 Dec 2001
  • Previous
  • 1
  • More pages
  • 154
  • 155
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863